Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Peter E. Fecci
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
9 hours ago Despite what tech CEOs might say, large language models are not smart in any recognizably human sense of the word. On June 13, 1863, a curious letter to the editor appeared in The Press, a then-fledgling New Zealand newspaper. Signed “Cellarius,” it warned of an encroaching “mechanical kingdom” that …
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding
Glioblastoma, the most common primary tumor of the central nervous system (CNS), remain uniformly aggressive and lethal, with a median survival of less than 2 years.1,2,3,4 Glioblastoma stem cells (GSCs) possess the fundamental stem cell properties including self-renewal, multi-potency, and tumor maintenance, and they share other characteristics with normal neural stem cells (NSCs).5,6 Although they comprise a small fraction of total tumor cells, GSCs have been demonstrated to promote tumor...
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
Immune checkpoint blockade (ICB) therapies have improved the outcome of patients with malignant tumors. However, most cancer patients barely benefit from ICB treatments.1 Deciphering mechanisms for ICB resistance, especially cancer cell-intrinsic factors mediating immune escape, will improve ICB efficacy.
Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion
Keywords T cell exhaustion tumor-associated macrophage tumor microenvironment tumor immunology immunotherapy brain tumor brain metastasis glioblastoma Introduction Brain tumors, both primary and metastatic, continue to herald poor survival.1,2 Immunotherapies, such as immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cells, hold promise for improving outcomes but remain only marginally effective within the intracranial confines.3,4 This has been especially true in the...
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling - Nature Medicine
A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials Therapeutic drug development in glioblastoma has remained static despite numerous clinical trials, advances in tumor biology, and substantial public interest. Since 2005, more than 1,250 interventional glioblastoma trials have been registered on ClinicalTrials.gov. Of these, 1,100 are phase 1 or 2 trials, most of which are dose-escalation studies.
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma - Nature Communications
Mice Six- to eight-week-old C57BL/6J, LysMcre, Syn1cre, and CD45.1 mice were purchased from the Jackson Laboratory. CaMKK2−/−, Tg(Camkk2-EGFP)DF129Gsat reporter mice (CaMKK2-EGFP), and CaMKK2fl/fl mice were generously provided by Luigi Racioppi (Duke University). CaMKK2−/−, CaMKK2-EGFP and CaMKK2fl/fl mice have been previously validated22. All transgenic mouse lines were derived from or have been previously backcrossed to the C57BL/6 background.
Current multidisciplinary management of brain metastases
Review Article Michael J. Moravan MD, PhD Corresponding Author E-mail address: michael.moravan@duke.edu https://orcid.org/0000-0003-2487-766X Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina Department of Radiation Oncology, Durham Veterans Affairs Medical Center, Durham, North Carolina Corresponding Author: Michael J.
Brain immunology and immunotherapy in brain tumours
1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005). CAS PubMed Article Google Scholar 2. Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392–401 (2006). CAS PubMed Article Google Scholar 3. Walker, M. D. et al.
Rescuing imperfect antigens for immuno-oncology
Targeting two antigens with BiTE-secreting CAR-T cells limits tumor immune escape in glioblastoma. Fig. 1: CART-BiTE cells target two antigens, EGFRvIII and wt EGFR, on GBM tumor cells. References 1. Choi, B.D. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-019-0192-1 (2019). 2. Fecci, P. E., Heimberger, A. B. & Sampson, J. H. Clin. Cancer Res. 20, 5620–5629 (2014). 3. Hodges, T. R. et al. Neuro-oncol. 19, 1047–1057 (2017). 4. Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A. & Fecci, P. E. Clin.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Peter E.
Contact Peter E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack